Amgen v. Sanofi ruling promotes competition within drug classes
Supreme Court decision puts an end to antibody genus claims. It could hurt more differentiated innovation
A Supreme Court ruling in Amgen Inc. v. Sanofi puts an official end to the use of broad genus claims in biopharma patent strategies, which cover all antibodies against a target site. It’s a decision that could stifle innovation, but it’s also consistent with recent court decisions.
In an opinion released on Thursday, SCOTUS ruled in favor of Sanofi (Euronext:SAN; NASDAQ:SNY) in a patent infringement case brought by Amgen Inc. (NASDAQ:AMGN) that involved cholesterol-lowering antibodies against PCSK9...